HCMSG - Hepatitis C Mentor & Support Group, Inc.
Search
  • About Us
    • Our Mission
    • Board of Directors
    • Medical Advisors
  • Resources
    • Corona Virus
    • Hep C Facts & Stats
    • Medications and Treatments >
      • Patient Assistance Programs
    • Reading
    • Links
  • Programs/Training
    • The Circle Model >
      • THE CIRCLE Registration
      • Group and Facilitator Guide
    • Hepatitis C Online Training
    • The Hepatitis C Education and Support Group Assistance Program
    • Healthcare Provider Training
  • Newsletter
  • Blog
  • Support Us
    • Holiday 2020
  • Contact Us

Hepatitis C Patients May Get Triaged For New Cures Based On Amount of Liver Damage

3/17/2014

1 Comment

 
Hepatitis C is now considered a “curable” disease by doctors, thanks to two new drugs – Olysio, manufactured by Johnson & Johnson, and the recently released Sovaldi, a product of Gilead Sciences. With very few side effects and a cure rate of as much as 95%, these drugs represent the much-needed break medical practitioners have been looking for in addressing the needs of a disease that has reached epidemic proportions. However, like many other cutting-edge drugs, the new Hepatitis C drugs come with a high price tag. Sovaldi costs $1,000 a pill, and Olysio is just a bit cheaper, priced at $850 a piece.

The high price on one hand and the urgency to provide treatment for chronic Hepatitis C Virus (HCV) infection on the other has become a dilemma for healthcare professionals, hospital representatives, insurers, and patient advocates including Medicaid as to how to go about administering these medicines. This was the agenda at a recent meeting for the California Technology Assessment Forum (CATF), a group affiliated with health insurers conducting meetings in the wake of advances made in treatment options. It was estimated that any line of treatment carried on with these two drugs could cost as much as $66,000 to $84,000 in one course — an amount that would make the entire health insurance system go bankrupt.

Finding a feasible solution to this issue was no less a challenge for the 15 member panel who convened the meeting. It was agreed upon however, that with the drug makers having defended their pricing, owing to the efficacy and potential against chronic HCV, there is currently no scope of a possible price reduction. According to Rena K. Fox, a professor of medicine at the University of California, San Francisco, “What I really wish for is that we could push back on the price, rather than make patients wait. But since we don’t have the ability to change the price, we have to decide which patients are the most urgent.” Hence, in a country where almost 3 to 5 million people are diagnosed by HCV every year, it became necessary to prioritize the needs of each patient by assessing the severity of infection.

HCV infections take a long time to diagnose, sometimes years or even decades, thanks to the disease’s non-specific symptoms. Hence, medical experts believe that the best course of action will be to treat those with a considerable amount of liver damage (pertaining to cirrhosis, fibrosis or cancer) first, in comparison to recently diagnosed patients with little or no liver damage at all.

Assessing the situation from an ethical point of view, Ryan Clary, executive director of the National Viral Hepatitis Roundtable, a consumer group partially funded by the drug industry, said that, “If I was hepatitis C-positive and someone said there’s this great treatment, but can you hold off because you’re healthy and it might bankrupt the system … patients don’t think like that!” But one does not have much of an option, given that the total estimated cost of treating every HCV infected patient in California alone comes up to $6.3 billion (according to a draft report prepared in advance for the meeting). Even  Medicaid insurers are worried as to how to cover up for the drugs for those in need immediately, and have asked the states for additional help.

Another major cause of concern would be marketing these drugs overseas, especially to the developing and third world countries where rates of infection with HCV are much higher.

A report with the committee’s recommendation will be published within a month, according to a report by the Washington Post (dated march 12, 2014).

 

1 Comment
friv 4 link
3/30/2014 12:43:25 pm

These studies and the results we see more of the factors related to hepatitis C, the best solution can be found and applied we always hope so.

Reply

Your comment will be posted after it is approved.


Leave a Reply.

    Archives

    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013
    December 2012
    November 2012
    October 2012
    September 2012
    August 2012
    July 2012
    June 2012
    May 2012
    April 2012
    March 2012
    February 2012
    January 2012
    December 2011
    November 2011
    October 2011
    September 2011
    August 2011
    July 2011
    June 2011
    May 2011

    Categories

    All

    RSS Feed

Privacy Policy